Evidence map›Paper›PMID 34837078›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2022

Rapid-acting antidepressants and the circadian clock.

Shogo Sato, Blynn Bunney, Lucia Mendoza-Viveros, William Bunney, Emiliana Borrelli, Paolo Sassone-Corsi, Ricardo Orozco-Solis

Open access · bronzeAbstract readReview
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Genetic determinants of antidepressant and antipsychotic drug response.European archives of psychiatry and clinical neuroscience · 2025
    Article
  12. Article
  13. Review
  14. Role of Sleep in Depressive Disorders and the Potential Therapeutic Role of Short-Term Sleep Deprivation and Light Therapy: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Shogo SatoCenter for Biological Clocks Research, Department of Biology, Texas A&M University, College Station, TX, USA.
Blynn BunneyDepartment of Psychiatry & Human Behavior, School of Medicine, University of California, Irvine, CA, USA.
Lucia Mendoza-ViverosInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México UNAM, México City, México.
William BunneyDepartment of Psychiatry & Human Behavior, School of Medicine, University of California, Irvine, CA, USA.
Emiliana BorrelliCenter for Epigenetics and Metabolism, INSERM U1223, Department of Microbiology and Molecular Genetics, University of California, Irvine, CA, USA.ORCID http://orcid.org/0000-0002-1813-2541
Paolo Sassone-CorsiCenter for Epigenetics and Metabolism, INSERM U1223, Department of Biological Chemistry, University of California Irvine, Irvine, CA, USA.
Ricardo Orozco-SolisInstituto Nacional de Medicina Genómica INMEGEN, México City, México. drorozcos@inmegen.gob.mx.ORCID http://orcid.org/0000-0003-1494-7281
University of California, Irvine · USNational Institute of Genomic Medicine · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing number of epidemiological and experimental studies has established that circadian disruption is strongly associated with psychiatric disorders, including major depressive disorder (MDD). This association is becoming increasingly relevant considering that modern lifestyles, social zeitgebers (time cues) and genetic variants contribute to disrupting circadian rhythms that may lead to psychiatric disorders. Circadian abnormalities associated with MDD include dysregulated rhythms of sleep, temperature, hormonal secretions, and mood which are modulated by the molecular clock. Rapid-acting antidepressants such as subanesthetic ketamine and sleep deprivation therapy can improve symptoms within 24 h in a subset of depressed patients, in striking contrast to conventional treatments, which generally require weeks for a full clinical response. Importantly, animal data show that sleep deprivation and ketamine have overlapping effects on clock gene expression. Furthermore, emerging data implicate the circadian system as a critical component involved in rapid antidepressant responses via several intracellular signaling pathways such as GSK3β, mTOR, MAPK, and NOTCH to initiate synaptic plasticity. Future research on the relationship between depression and the circadian clock may contribute to the development of novel therapeutic strategies for depression-like symptoms. In this review we summarize recent evidence describing: (1) how the circadian clock is implicated in depression, (2) how clock genes may contribute to fast-acting antidepressants, and (3) the mechanistic links between the clock genes driving circadian rhythms and neuroplasticity.

Indexed as

Circadian ClocksMajor Depressive DisorderAnimalsAntidepressive AgentsCircadian RhythmHumansSleep DeprivationAntidepressive Agents

Identifiers

PMID34837078
PMCPMC8626287
OpenAlexW3217489025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.